Google Scholar | Citations: 16429| h-index: 32 | i10-index: 482
Evaluation of the profile and spacial distribution of COVID-19 in the Central-West region of Brazil, in the period of 2020-2022
PDF (Portuguese (Brazil))

Keywords

COVID-19
Health indicators
Epidemiology

How to Cite

Evaluation of the profile and spacial distribution of COVID-19 in the Central-West region of Brazil, in the period of 2020-2022. (2024). Electronic Journal Collection Health, 24(1), e14345. https://doi.org/10.25248/reas.e14345.2024

Copyright © | All rights reserved.

The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.

Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.

Total reproduction
It is expressly prohibited and must be authorized by the journal.

Abstract

Objective: To assess the profile and spatial distribution of Covid-19 in the Midwest region of Brazil between 2020 and 2022. Methods: Descriptive study of Covid-19 cases and deaths and acquisition of health equipment in the pandemic. Results: There was an increase in Covid-19 in the Federal District (8959.3/2020-12838.8/2022) and Goiás (8759.2/2020-24620.2/2022); mortality decreased in all states. In general, there were more cases among women (<0.0001) and deaths among men (<0.0001). In cities with a higher population, mortality and lethality showed a decrease, as opposed to those with a lower density. In terms of the distribution of Intensive Care Unit (ICU) beds, there was greater distribution in the inland areas, and greater occupancy in the capitals (between 67.8%-82.5% vs. 58.6%-77.8% in the inland areas); over the period, the capitals and inland areas showed an increase in occupancy. Around 1,465 ICU ventilators and 1,786 Mobile Emergency Care Service (SAMU) were purchased in the region, with R$124,392,248.94 invested. R$12,696.00 and R$6,477,309.69 were spent on the distribution of medications used in the pandemic, especially chloroquine and osetalmivir. Conclusion: There were differences in the evolution of Covid-19, vulnerability in population groups and incipient and unnecessary spending on drugs with no scientific evidence, thus the need for a coordinated approach to tackle the pandemic.

PDF (Portuguese (Brazil))

References

ALMEIDA G, et al. Primary health care quality and its association with the prevalence of comorbidities in Brazilian urban areas. Health Policy and Planning, 2021; 36(2): 112-121.

BAKER MA, et al. Estimating the economic value of vaccines in low- and middle-income countries: A systematic review. Health Affairs, 2021; 40 (4): 590-602.

BANHOLZER N, et al. Impact of non-pharmaceutical interventions on documented cases of COVID-19. MedRxiv, 2020.

BETSCH C, et al. Social and behavioral consequences of mask policies during the COVID-19 pandemic. Proceedings of the National Academy of Sciences, 2020; 117(36): 21851-21853.

BWIRE GM. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? SN Comprehensive Clinical Medicine, 2021.

BRASIL. Ministério da Saúde. Programa Nacional de Imunizações. Cobertura vacinal em regiões menos populosas. Brasília, DF, 2022.

CENTROS DE CONTROLE E PREVENÇÃO DE DOENÇAS. Vacinação e prevenção de doenças infecciosas. Atlanta, 2022.

CHOWELL G, et al. COVID-19 vaccines: modes of immune activation and future challenges. Nature Reviews Immunology, 2021; 21(4):195-197.

FIGUEIREDO TD e ESCOBAR, A. Possíveis efeitos do relaxamento não controlado das medidas de isolamento social no comportamento da pandemia por COVID-19: um exercício com os dados reais de Rondônia, Estado do Sudoeste da Amazônia Brasileira, 2020.

GATTINONI L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Medicine, 2020.

GAUTRET P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, 2020: 56 (1).

GEBHARD C, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biology of Sex Differences, 2020.

GRASSELLI G, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA, 2020; 323(16).

HORBY P, et al. Dexamethasone in hospitalized patients with Covid-19. New England Journal of medicine, 2020.

INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA (IBGE). Panorama da Região Centro-Oeste. 2021.

KEECH M, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. The New England Journal of medicine, 2020; 383 (24):2320-2332.

LANA RM, et al. Emergência do novo coronavírus (SARS-CoV-2) e o papel de uma vigilância nacional em saúde oportuna e efetiva. Cadernos de Saúde Pública, 2020.

LEDFORD H. High-profile coronavirus retractions raise concerns about data oversight. Nature, 2020; 582: 160.

LEGIDO-QUIGLEY H, et al. Are high-performing health systems resilient against the COVID-19 epidemic? The Lancet, 2020.

LEVY BS e SIDEL VW. COVID-19 and older adults: persisting problems and the need for a social safety net. Public Health Reports, 2020; 135(5): 605-608.

MALTA DO. A pandemia de COVID-19 para além das Ciências da Saúde: Reflexões sobre sua determinação social. Ciência & Saúde Coletiva, 2020.

MARTINS GA. Manual para elaboração de projetos e relatórios de pesquisa. 6. ed. São Paulo: Atlas, 2012.

MINEIROS. Secretaria Municipal de Saúde. Boletim epidemiológico especial – nº 04. Mineiros, 2020.

NIKOLICH-ZUGICH J, et al. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. GeroScience, 2020.

NOGUEIRA PJ, et al. COVID-19 in Portugal: exploring the immediate challenges for public health. Journal of Public Health, 2020; 42(4): 649-651.

ORGANIZAÇÃO PAN AMERICA DA SAÚDE (OPAS). Vacinas contra a COVID-19. Genebra, 2022.

POLACK FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. The New England Journal of medicine, 2020.

RANDOLPH HE e BARREIRO LB. Herd immunity: understanding COVID-19. Immunity, 2020; 52 (5).

RANNEY ML, et al. Critical supply shortages — the need for ventilators and personal protective equipment during the Covid-19 pandemic. New England Journal of medicine, 2020.

RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 2020: 396: 1345-1352.

ROCKLÖV J e SJÖDIN H. High population densities catalyze the spread of COVID-19. Journal of Travel Medicine, 2020; 27 (3): 1-2.

SANTOS LMP, et al. Implementation research: towards universal health coverage with more doctors in Brazil. Bulletin of the World Health Organization, 2020; 95 (2):103-112.

SCULLY EP, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nature Reviews Immunology, 2021.

SILVA GJB, et al. Mortality and survival of COVID-19. Epidemiology & Infection, 2020.

SOUZA WM, et al. Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nature Human Behaviour, 2021; 4: 856–865.

TAKAHASHI T, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature, 2020; 588: 315-320.

VAN BAVEL JJ, et al. Using social and behavioural science to support COVID-19 pandemic response. Nature Human Behaviour, 2020; 4 (5); 460-471.

VAN DAMME W, et al. The COVID-19 pandemic: diverse contexts; different epidemics—how and why? BMJ Global Health, 2021.

WADHERA RK, et al. Variation in COVID-19 hospitalizations and deaths across New York City boroughs. JAMA, 2020: 2192-2195.

ZUMLA A, et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. The Lancet, 2020.